Citations

Showing 10 of 108119 citations.

Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review
Bokemeyer, Arne , Baker, Mark E. , Mao, Ren, Parker, Claire E. , Nguyen, Tran M , Feagan, Brian G. , Rieder, Florian , Bettenworth, Dominik , Bokemeyer, Arne , Ma, Christopher , Panés, Julián , Rimola, Jordi , Fletcher, Joel G. , Jairath, Vipul

Mayo Clinic

Gut | April 3, 2019 | Volume: 68 | Issue: 6 | Pages: 1115-1126

10.1136/gutjnl-2018-318081 | PMID 30944110 Get It

Patients with Crohn’s disease commonly develop ileal and less commonly colonic strictures, containing various degrees of inflammation and fibrosis. While predominantly inflammatory strictures may benefit from a medical anti-inflammatory treatment, predominantly fibrotic strictures currently require endoscopic balloon dilation or surgery. Therefore, differentiation of the main components of a stricturing lesion is key for defining the therapeutic management. The role of endoscopy to diagnose the nature of strictures is limited by the superficial inspection of the intestinal mucosa, the lack of depth of mucosal biopsies and by the risk of sampling error due to a heterogeneous distribution of inflammation and fibrosis within a stricturing lesion. These limitations may be in part overcome by cross-sectional imaging techniques such as ultrasound, CT and MRI, allowing for a full thickness evaluation of the bowel wall and associated abnormalities. This systematic literature review provides a comprehensive summary of currently used radiologic definitions of strictures. It discusses, by assessing only manuscripts with histopathology as a gold standard, the accuracy for diagnosis of the respective modalities as well as their capability to characterise strictures in terms of inflammation and fibrosis. Definitions for strictures on cross-sectional imaging are heterogeneous; however, accuracy for stricture diagnosis is very high. Although conventional cross-sectional imaging techniques have been reported to distinguish inflammation from fibrosis and grade their severity, they are not sufficiently accurate for use in routine clinical practice. Finally, we present recent consensus recommendations and highlight experimental techniques that may overcome the limitations of current technologies.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies
Laubach, Jacob P. , Gutierrez, Maria Asunción Echeveste, Grząśko, Norbert , Miguel, Jesús F. San , Kumar, Shaji , Labotka, Richard, Lu, Vickie, Berg, Deborah, Byrne, Catriona , Teng, Zhaoyang , Liu, Guohui , Velde, Helgi van de , Richardson, Paul G. , Dimopoulos, Meletios A , San-Miguel, Jesus , Dimopoulos, Meletios Α. , Hofmeister, Craig C. , Richardson, Paul Gerard Guy

Mayo Clinic

European Journal of Haematology | April 3, 2019 | Volume: 102 | Issue: 6 | Pages: 494-503

10.1111/ejh.13231 | PMID 30943323 Get It

AbstractObjectivesTo evaluate the safety and efficacy of maintenance therapy with the oral proteasome inhibitor ixazomib in patients with newly diagnosed multiple myeloma (NDMM) not undergoing transplantation.MethodsData were pooled from four NDMM phase I/II studies; patients received induction therapy with once‐ or twice‐weekly ixazomib plus lenalidomide‐dexamethasone (IRd), melphalan‐prednisone (IMP), or cyclophosphamide‐dexamethasone (ICd), followed by single‐agent ixazomib maintenance, given at the last tolerated dose during induction, until disease progression, death, or unacceptable toxicity.ResultsA total of 121 patients achieved stable disease or better after induction (weekly IRd, n = 25; twice‐weekly IRd, n = 18; weekly or twice‐weekly IMP, n = 35; weekly ICd, n = 43) and received ≥ 1 dose of ixazomib maintenance. Grade ≥ 3 drug‐related adverse events occurred in 24% of patients during maintenance; each event was reported in ≤2% of patients. Rates of complete response were 22% after induction and 35% after maintenance. A total of 28 patients (23%) improved their response during maintenance.ConclusionsIxazomib maintenance following ixazomib‐based induction is associated with deepening of responses and a positive safety profile with no cumulative toxicity in patients with NDMM not undergoing transplantation, suggesting that ixazomib is feasible for long‐term administration. Phase III investigation of ixazomib maintenance is ongoing.
An Introduction to RA21: Taking Authentication Beyond IP Addresses
Hoy, Matthew B.

Mayo Clinic

Medical Reference Services Quarterly | April 3, 2019 | Volume: 38 | Issue: 1 | Pages: 81-86

10.1080/02763869.2019.1554370 | PMID 30942682 Get It

Re: Wrong way go back: lessons learned from a misguided chest drain
Rajesh, Aashish , Chandra, Abhishek , Farley, David R. , Chandra, Abhishek

Mayo Clinic

ANZ Journal of Surgery | April 3, 2019 | Volume: 89 | Issue: 4 | Pages: 450-451

10.1111/ans.15127 | PMID 30942542 Get It

Re: Axial torsion of Meckel's diverticulum
Rajesh, Aashish , Chandra, Abhishek

Mayo Clinic

ANZ Journal of Surgery | April 3, 2019 | Volume: 89 | Issue: 4 | Pages: 447-449

10.1111/ans.15110 | PMID 30942545 Get It

Re: Adenocarcinoma in a Meckel's diverticulum presenting as a phlegmon: a case report and a review of the literature
Rajesh, Aashish

Mayo Clinic

ANZ Journal of Surgery | April 3, 2019 | Volume: 89 | Issue: 4 | Pages: 446-446

10.1111/ans.15101 | PMID 30942540 Get It

Elevated intracellular trypsin exacerbates acute pancreatitis and chronic pancreatitis in mice
Zhan, Xianbao , Wan, Jianhua , Zhang, Guowei , Song, Lele , Gui, Fu , Zhang, Yuebo , Li, Yinghua , Guo, Jia , Dawra, Rajinder , Saluja, Ashok K. , Haddock, Ashley , Zhang, Lizhi , Bi, Yan , Ji, Baoan , Haddock, Ashley N, Zhan, Xianbao , Gui, Fu

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | April 3, 2019 | Volume: 316 | Issue: 6 | Pages: G816-G825

10.1152/ajpgi.00004.2019 | PMID 30943050 Get It

Intra-acinar trypsinogen activation occurs in the earliest stages of pancreatitis and is believed to play important roles in pancreatitis pathogenesis. However, the exact role of intra-acinar trypsin activity in pancreatitis remains elusive. Here, we aimed to examine the specific effects of intra-acinar trypsin activity on the development of pancreatitis using a transgenic mouse model. This transgenic mouse model allowed for the conditional expression of a mutant trypsinogen that can be activated specifically inside pancreatic acinar cells. We found that expression of this active mutated trypsin had no significant effect on triggering spontaneous pancreatitis. Instead, several protective compensatory mechanisms, including SPINK1 and heat shock proteins, were upregulated. Notably, these transgenic mice developed much more severe acute pancreatitis, compared with control mice, when challenged with caerulein. Elevated tissue edema, serum amylase, inflammatory cell infiltration and acinar cell apoptosis were dramatically associated with increased trypsin activity. Furthermore, chronic pathological changes were observed in the pancreas of all transgenic mice, including inflammatory cell infiltration, parenchymal atrophy and cell loss, fibrosis, and fatty replacement. These changes were not observed in control mice treated with caerulein. The alterations in pancreata from transgenic mice mimicked the histological changes common to human chronic pancreatitis. Taken together, we provided in vivo evidence that increased intra-acinar activation of trypsinogen plays an important role in the initiation and progression of both acute and chronic pancreatitis. NEW & NOTEWORTHY Trypsinogen is activated early in pancreatitis. However, the roles of trypsin in the development of pancreatitis have not been fully addressed. Using a genetic approach, we showed trypsin activity is critical for the severity of both acute and chronic pancreatitis.
MAGI1 as a link between endothelial activation and ER stress drives atherosclerosis
Abe, Jun‐ichi , Ko, Kyung Ae , Kotla, Sivareddy , Paez‐Mayorga, Jesus , Shin, Ik Jae , Imanishi, Masaki , Vu, Hang Thi, Tao, Yunting, Leiva‐Juárez, Miguel M. , Thomas, Tamlyn , Medina, Jan L., Won, Jong Hak, Fujii, Yuka , Giancursio, Carolyn J., McBeath, Elena , Shin, Ji-Hyun, Guzman, Liliana , Abe, Rei , Taunton, Jack , Faubion, William A. , Fujiwara, Keigi , Evans, Scott E. , Le, Nhat‐Tu , Faubion, William, Abe, Rei J , Kotla, Sivareddy , Abe, Jun-Ichi , Wang, Yin , Shin, Ji‐Hyun , Mochizuki, Naoki , Cooke, John P. , Le, Nhat-Tu

Mayo Clinic

JCI Insight | April 3, 2019 | Volume: 4 | Issue: 7 | Pages: No page available

10.1172/jci.insight.125570 | PMID 30944250 Get It

The possible association between the membrane-associated guanylate kinase with inverted domain structure-1 (MAGI1) and inflammation has been suggested, but the molecular mechanisms underlying this link, especially during atherogenesis, remain unclear. In endothelial cells (ECs) exposed to disturbed flow (d-flow), p90 ribosomal S6 kinase (p90RSK) bound to MAGI1, causing MAGI1-S741 phosphorylation and sentrin/SUMO-specific protease 2 T368 phosphorylation-mediated MAGI1-K931 deSUMOylation. MAGI1-S741 phosphorylation upregulated EC activation via activating Rap1. MAGI1-K931 deSUMOylation induced both nuclear translocation of p90RSK-MAGI1 and ATF-6-MAGI1 complexes, which accelerated EC activation and apoptosis, respectively. Microarray screening revealed key roles for MAGI1 in the endoplasmic reticulum (ER) stress response. In this context, MAGI1 associated with activating transcription factor 6 (ATF-6). MAGI1 expression was upregulated in ECs and macrophages found in atherosclerotic-prone regions of mouse aortas as well as in the colonic epithelia and ECs of patients with inflammatory bowel disease. Further, reduced MAGI1 expression in Magi1 –/+ mice inhibited d-flow–induced atherogenesis. In sum, EC activation and ER stress–mediated apoptosis are regulated in concert by two different types of MAGI1 posttranslational modifications, elucidating attractive drug targets for chronic inflammatory disease, particularly atherosclerosis.
Remote ischemic preconditioning for elective endovascular intracranial aneurysm repair: a feasibility study
Seyedsaadat, Seyed Mohammad , Castilla, Leonardo Rangel, Cloft, Harry J. , Blezek, Daniel J. , Theiler, A. , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Mohammad Seyedsaadat, Seyed , Rangel Castilla, Leonardo, Theiler, Amy, Lanzino, Giuseppe

Mayo Clinic

The Neuroradiology Journal | April 3, 2019 | Volume: 32 | Issue: 3 | Pages: 166-172

10.1177/1971400919842059 | PMID 30942660 Get It

Objectives Remote ischemic preconditioning has been proposed as a possible potential treatment for ischemic stroke. However, neuroprotective benefits of the pre-procedural administration of remote ischemic preconditioning have not been investigated in patients undergoing an elective endovascular intracranial aneurysm repair procedure. This study investigated the safety and feasibility of remote ischemic preconditioning in patients with an unruptured intracranial aneurysm who undergo elective endovascular treatment. Methods In this single-center prospective study, patients with an unruptured intracranial aneurysm undergoing elective endovascular treatment with flow diverters or coiling were recruited. Patients received three intermittent cycles of 5 minutes arm ischemia followed by reperfusion using manual blood cuff inflation/deflation less than 5 hours prior to endovascular treatment. Patients were monitored and followed up for remote ischemic preconditioning-related adverse events and ischemic brain lesions by diffusion -weighted magnetic resonance imaging within 48 hours following endovascular treatment. Results A total of seven patients aged 60 ± 5 years with an unruptured intracranial aneurysm successfully completed a total of 21 sessions of remote ischemic preconditioning and the required procedures. Except for two patients who developed skin petechiae over their arms, no other serious procedure-related adverse events were observed as a result of the remote ischemic preconditioning procedure. On follow-up diffusion -weighted magnetic resonance imaging, a total of 19 ischemic brain lesions with a median (interquartile range) volume of 245 (61–466) mm 3 were found in four out of seven patients. Conclusions The application of remote ischemic preconditioning prior to endovascular intracranial aneurysm repair was well tolerated, safe and clinically feasible. Larger sham-controlled clinical trials are required to determine the safety and efficacy of this therapeutic strategy in mitigating ischemic damage following endovascular treatment of intracranial aneurysms.